General Information of the Compound
Compound ID
CP0007111
Compound Name
(2S)-2-[[2-(1-benzofuran-6-carbonyl)-5,7-dichloro-3,4-dihydro-1H-isoquinoline-6-carbonyl]amino]-3-(3-methylsulfonylphenyl)propanoic acid
    Show/Hide
Synonyms
SAR-1118
(S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid
(S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid;(S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid
038E5L962W
1025967-78-5
CHEMBL2048028
Lifitegrast
SAR 1118
SAR-1118
SAR-1119
SHP606
SPD606
UNII-038E5L962W
Xiidra
lifitegrast
    Show/Hide
Structure
Formula
C29H24Cl2N2O7S
Molecular Weight
615.491
Canonical SMILES
CS(=O)(=O)c1cccc(C[C@H](NC(=O)c2c(Cl)cc3CN(CCc3c2Cl)C(=O)c2ccc3ccoc3c2)C(O)=O)c1
    Show/Hide
InChI
InChI=1S/C29H24Cl2N2O7S/c1-41(38,39)20-4-2-3-16(11-20)12-23(29(36)37)32-27(34)25-22(30)13-19-15-33(9-7-21(19)26(25)31)28(35)18-6-5-17-8-10-40-24(17)14-18/h2-6,8,10-11,13-14,23H,7,9,12,15H2,1H3,(H,32,34)(H,36,37)/t23-/m0/s1
    Show/Hide
InChIKey
JFOZKMSJYSPYLN-QHCPKHFHSA-N
CAS
1025967-78-5
Physicochemical Property
logP
4.7673
Rotatable Bonds
7
Heavy Atom Count
41
Polar Areas
133.99
Hydrogen Bond Donor Count
2
Hydrogen Bond Acceptor Count
6
Complexity
41

"RO5" indicates the cutoff set by lipinski's rule of five:

(1) Molecular weight less than 500 Dalton;

(2) xlogp less than 5;

(3) No more than 5 hbonddonor (Hydrogen Bond Donor Count);

(4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count);

(5) No more than 10 rotbonds (Rotatable Bond Count).

    Show/Hide
Click to Show/Hide the External Link(s) of This Compound
PubChem ID
CID: 11965427
SID: 17424515
ChEMBL ID
CHEMBL2048028
DrugBank ID
DB11611
Clinical Information about the Compound
Drug 1 ( lifitegrast )
Drug Name lifitegrast
Company Shire Pharmaceuticals
Indication
Dry eye disease
Approved
Allergic conjunctivitis
Phase 3
Target(s)
Intercellular adhesion molecule ICAM-1 (ICAM1)
Inhibitor
Integrin alpha-L (ITGAL)
Modulator